While intraocular VEGF antagonists have been recently used to treat severe ROP, they were observed to have possible systemic anti-angiogenic effects that are detrimental to the development of other organs, such as the lung and brain, and they do not correct retinal neuronal injury8. Here, VEGFA is linked to retinopathy of prematurity.